Athersys (NASDAQ:ATHX) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Athersys in a research note on Monday, March 6th. They issued a “buy” rating and a $5.50 price objective for the company.

Athersys Price Performance

Shares of NASDAQ:ATHX opened at $1.31 on Thursday. The company has a market capitalization of $14.42 million, a PE ratio of -0.17 and a beta of -0.74. The business has a fifty day moving average price of $1.50 and a two-hundred day moving average price of $1.45. Athersys has a 1 year low of $0.50 and a 1 year high of $33.25.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD purchased a new position in shares of Athersys during the 4th quarter valued at $36,000. Private Advisor Group LLC purchased a new position in shares of Athersys during the 1st quarter valued at $27,000. Virtu Financial LLC lifted its position in shares of Athersys by 169.8% during the 1st quarter. Virtu Financial LLC now owns 92,846 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 58,432 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Athersys by 67.3% during the 4th quarter. Renaissance Technologies LLC now owns 99,936 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 40,200 shares during the last quarter. Finally, Eqis Capital Management Inc. lifted its position in shares of Athersys by 605.9% during the 2nd quarter. Eqis Capital Management Inc. now owns 123,990 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 106,426 shares during the last quarter. Hedge funds and other institutional investors own 20.23% of the company’s stock.

About Athersys

(Get Rating)

Athersys, Inc engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.